Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMINOLEVULINIC ACID for Bladder transitional cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 15 adverse event reports in the FDA FAERS database where AMINOLEVULINIC ACID was used for Bladder transitional cell carcinoma.

Most Reported Side Effects for AMINOLEVULINIC ACID

Side Effect Reports % Deaths Hosp.
Drug ineffective 293 17.8% 0 0
Off label use 178 10.8% 1 3
Wrong technique in product usage process 173 10.5% 0 2
Erythema 144 8.8% 0 1
Product quality issue 132 8.0% 0 0
Poor quality product administered 124 7.6% 0 0
Pain 102 6.2% 0 4
Product dose omission issue 93 5.7% 0 0
Application site pain 90 5.5% 0 6
Application site erythema 81 4.9% 0 4
Accidental exposure to product 73 4.4% 0 0
Blister 52 3.2% 0 0
Product physical issue 48 2.9% 0 0
Oedema 36 2.2% 0 0
Eye irritation 35 2.1% 0 1

Other Indications for AMINOLEVULINIC ACID

Product used for unknown indication (765) Actinic keratosis (466) Photodynamic diagnostic procedure (63) Photodynamic therapy (55) Acne (35) Squamous cell carcinoma of skin (34) Glioblastoma (23) Glioma (10) Skin disorder (8) Skin cancer (7)

Other Drugs Used for Bladder transitional cell carcinoma

GEMCITABINE (335) CISPLATIN (252) PEMBROLIZUMAB (251) ATEZOLIZUMAB (195) CARBOPLATIN (146) BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119) AVELUMAB (104) DURVALUMAB (88) NIVOLUMAB (80) ENFORTUMAB VEDOTIN-EJFV (68)

Related Pages

AMINOLEVULINIC ACID Full Profile All Bladder transitional cell carcinoma Drugs AMINOLEVULINIC ACID Demographics AMINOLEVULINIC ACID Timeline